The field of molecular building blocks in my country is gradually forming a scale, and the investment space is broad

[Pharmaceutical Network Market Analysis] Molecular building blocks are small molecular compounds used to design and construct active pharmaceutical substances.
They belong to the underlying structure compounds, which are rich in variety and novel in structure.
Generally, the molecular weight is less than 300
.

Using and combining different molecular building blocks in the drug development stage can quickly obtain a large number of candidate compounds for screening and evaluation, efficiently evaluate the relationship between compound structure and activity, and finally determine clinical candidate compounds
.

In the domestic market, molecular building blocks are widely used as scientific research reagents by researchers in scientific research institutes, universities, and pharmaceutical companies.
They feature a wide variety of products and scattered customers
.

It is reported that many domestic enterprises have significant advantages in molecular building blocks
.

For example, molecular building blocks are "adding bricks and bricks" to the listing process of Bide Pharmaceuticals.
According to public information, Bide Pharmaceuticals is a new drug research and development institution focusing on the new drug research and development industry chain, relying on the core business of research and development, design, production and sales of drug molecular building blocks.
It is a high-tech enterprise that provides products such as drug molecular building blocks and scientific reagents with novel structures and diverse functions
.

At present, Bide Pharma has the ability to provide more than 300,000 kinds of drug molecular building blocks with novel structure and various functions to new drug research and development institutions, of which more than 70,000 kinds of drug molecular building blocks are in stock, which has significant advantages in drug molecular building blocks
.

Not only that, Bide Pharmaceuticals has established regional centers in global new drug R&D highlands such as the United States, Europe, and India, so as to keep up with the frontier R&D direction of pharmaceuticals, develop drug molecular building blocks with unique structures and diverse functions in a timely manner, and quickly respond to customer requests for drug molecules.
The diverse needs of building blocks and scientific reagents help global new drug research and development institutions to accelerate the process of new drug research and development
.

 　　Haoyuan Pharmaceutical recently stated on the investor interaction platform that with its technical advantages in medicinal chemistry and organic synthesis, as well as years of experience in the small molecule drug research and development industry, the company has relatively new product categories in the field of molecular building blocks and tool compounds.
, complete, is one of the important players in the market segment, forming independent brands such as "MCE" and "Leyan"
.

The data shows that in 2021, the company's molecular building blocks and tool compounds business achieved a year-on-year increase of 57.
59% in operating income to 545 million yuan
.

As of the end of 2021, Haoyuan Pharmaceutical has accumulated more than 58,600 molecular building blocks and tool compounds
.

During the reporting period, the number of orders for molecular building blocks exceeded 163,000, and the number of orders for tool compounds exceeded 116,000
.

 　　Yaoshi Technology started with the research, development and design of molecular building blocks, and is a leading supplier of domestic drug molecular building blocks
.

The company's molecular building block products have outstanding advantages
.

As of H1 in 2021, the company has designed more than 130,000 compounds, and has conducted research and analysis on nearly 700 preclinical, clinical phase I to III and some listed compounds.
In the first half of the year alone, more than 500 new popular molecules have been added.
Blocks, which basically cover all current hot target compounds, such as key fragments of KRAS, SHP2, BTK and other inhibitors
.

Relying on the core molecular building block business, Yaoshi Technology has experienced rapid growth in revenue and performance in recent years
.

Data shows that from 2015 to 2020, the company's revenue CAGR is as high as 50%, and the non-returnable net profit CAGR is as high as 56%
.

In the first three quarters of 2021, the company achieved a revenue of 903 million yuan, a year-on-year increase of 24.
47%, and a net profit of 201 million yuan after deduction, a year-on-year increase of 49.
19%
.

 　　Molecular building blocks play an important role in pharmaceutical production.
Benefiting from the continuous growth of global and Chinese pharmaceutical R&D expenditures, the market demand for molecular building blocks has risen, and the market size has also shown an increasing trend
.

The industry said that the field of molecular building blocks in my country is gradually forming a scale, and more and more pharmaceutical intermediates and molecular building blocks enterprises have formed a trend of localization, and the future investment space is broad.

.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.